PulseSight Therapeutics Launches With Age-Related Macular Disease Gene Therapy Pipeline Posted on February 28, 2024January 18, 2026 by edgover
PulseSight Therapeutics launches to advance non-viral gene therapies Posted on February 28, 2024January 18, 2026 by edgover
[Funding alert] Paris-based PulseSight Therapeutics Secures an Undisclosed Amount in Seed Funding Posted on February 28, 2024January 18, 2026 by edgover
PulseSight Therapeutics launches to advance non-viral gene therapies Posted on February 28, 2024January 18, 2026 by edgover
Launch of PulseSight Therapeutics: advancing non-viral gene therapy for eye diseases Posted on February 28, 2024January 18, 2026 by edgover
PulseSight Therapeutics Will Develop Next Generation Eye Gene Therapies Posted on February 28, 2024January 18, 2026 by edgover
PulseSight unveils minimally invasive gene therapies for eye diseases Posted on February 28, 2024January 18, 2026 by edgover
![[Funding alert] Paris-based PulseSight Therapeutics Secures an Undisclosed Amount in Seed Funding](https://pulsesight.com/wp-content/uploads/2026/01/Paris-based-PulseSight-Therapeutics-Secures-an-Undisclosed-amount-in-Seed-Funding.webp)
